RxDoctor Payments DataLook up a doctor →

John Bertelson, MD

Behavioral Neurology & Neuropsychiatry · Austin, TXNPI 1215959697

Payments from drug & device makers

$668,724in general payments, 2019–2025

Across 585 payments — averaging $1143.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eisai Inc.$247K
  • Eli Lilly$179K
  • E.r. Squibb & Sons, L.L.C.$177K
  • Lilly USA, LLC$33K
  • Biogen$26K
  • Onmark, Inc.$1K
  • plus $5K from 30 others

What the payments were for

  • Consulting fees$23,3947%
  • Speaking & faculty fees$257,95682%
  • Travel & lodging$20,0046%
  • Food & beverage$11,5584%
  • Education$30%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few behavioral neurology & neuropsychiatry providers in Texasto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$54,147
Medicare patients
183
Services billed
337

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NamzaricMemantine Hcl/Donepezil Hcl14$22,683
Memantine Hcl ErMemantine Hcl194$14,846
Rivastigmine59$7,460
XareltoRivaroxaban13$6,702
Donepezil Hcl158$1,990
Memantine Hcl59$1,942
Sertraline Hcl41$631
Duloxetine Hcl31$612
Escitalopram Oxalate74$534
Divalproex Sodium ErDivalproex Sodium15$494
Montelukast Sodium12$360
Risperidone19$252
Trazodone Hcl12$211
Mirtazapine15$91
Levothyroxine Sodium12$67

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieNamzaric$135$22,68314 claims
Johnson & JohnsonXarelto$554$6,70213 claims
Almatica Pharma LLCSertraline Hcl$22$63141 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few behavioral neurology & neuropsychiatry providers in Texason file to place this against a meaningful peer group, so we don't.

Other behavioral neurology & neuropsychiatry in Austin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →